Likewise, immunoneutralization of TGF-β in vivo almost completely blunted PDAC-mediated diabetes, implicating TGF-β signaling as a possible target for attenuating diabetes in pancreatic cancer patients. This evidence concerns the gene TGFB1 and pancreatic neoplasm.